{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:46:40Z","timestamp":1789501600691,"version":"build-2803163510"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific research project of Henan National Center for inheritance and innovation of traditional Chinese medicine in 2023","award":["2023ZXZX1067"],"award-info":[{"award-number":["2023ZXZX1067"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03569-x","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:56:58Z","timestamp":1759921018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors"],"prefix":"10.1007","volume":"16","author":[{"given":"Lihao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"1","key":"3569_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cac2.12377","volume":"43","author":"H Yang","year":"2023","unstructured":"Yang H, Zhou X, Fu D, et al. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Commun (London England). 2023;43(1):42\u201374.","journal-title":"Cancer Commun (London England)"},{"issue":"10","key":"3569_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2174\/1381612825666190506122228","volume":"25","author":"S Chen","year":"2019","unstructured":"Chen S, Li F, Xu D, et al. The function of RAS mutation in cancer and advances in its drug research. Curr Pharm Design. 2019;25(10):1105\u201314.","journal-title":"Curr Pharm Design"},{"issue":"14","key":"3569_CR3","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969\u201374.","journal-title":"Cancer Res"},{"issue":"4","key":"3569_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41401-023-01194-4","volume":"45","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liu QP, Xie H, et al. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta Pharmacol Sin. 2024;45(4):686\u2013703.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"3569_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","volume":"32","author":"S Stickler","year":"2024","unstructured":"Stickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer. Oncol Res. 2024;32(5):799\u2013805.","journal-title":"Oncol Res"},{"issue":"4","key":"3569_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39(4):1029\u201338.","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"3569_CR7","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, et al. Biochemical and structural analysis of common Cancer-Associated KRAS mutations. Mol Cancer Res. 2015;13(9):1325\u201335.","journal-title":"Mol Cancer Res"},{"issue":"23","key":"3569_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2174\/1381612828666220506144046","volume":"28","author":"A Wadood","year":"2022","unstructured":"Wadood A, Ajmal A, Rehman AU. Strategies for targeting KRAS: A challenging drug target. Curr Pharm Design. 2022;28(23):1897\u2013901.","journal-title":"Curr Pharm Design"},{"issue":"1","key":"3569_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Therapy. 2021;6(1):386.","journal-title":"Signal Transduct Target Therapy"},{"issue":"23","key":"3569_CR10","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.2174\/1568026619666190905164144","volume":"19","author":"HZ Wu","year":"2019","unstructured":"Wu HZ, Xiao JQ, Xiao SS, et al. KRAS: A promising therapeutic target for cancer treatment. Curr Top Med Chem. 2019;19(23):2081\u201397.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"3569_CR11","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30(4):969\u201383.","journal-title":"Nat Med"},{"issue":"4","key":"3569_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10555-020-09911-9","volume":"39","author":"Z Orgov\u00e1n","year":"2020","unstructured":"Orgov\u00e1n Z, Keser\u0171 GM. Small molecule inhibitors of RAS proteins with oncogenic mutations. Cancer Metastasis Rev. 2020;39(4):1107\u201326.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3569_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C-Specific inhibitor. Cell. 2018;172(3):578\u2013e58917.","journal-title":"Cell"},{"issue":"10","key":"3569_CR14","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/acsmedchemlett.3c00245","volume":"14","author":"H Cheng","year":"2023","unstructured":"Cheng H, Li P, Chen P, et al. Structure-based design and synthesis of potent and selective KRAS G12D inhibitors. ACS Med Chem Lett. 2023;14(10):1351\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"3569_CR15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/10600280231197459","volume":"58","author":"N Mausey","year":"2024","unstructured":"Mausey N, Halford Z. Targeted therapies for previously undruggable KRAS-Mutated Non-Small cell lung cancer: A review of Sotorasib and adagrasib. Annals Pharmacotherapy. 2024;58(6):622\u201335.","journal-title":"Annals Pharmacotherapy"},{"issue":"10","key":"3569_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, et al. The current state of the Art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3569_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman BA, Allen JR, Allen JG, et al. Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63(1):52\u201365.","journal-title":"J Med Chem"},{"key":"3569_CR18","doi-asserted-by":"publisher","first-page":"117955492513317","DOI":"10.1177\/11795549251331759","volume":"19","author":"S El Zaitouni","year":"2025","unstructured":"El Zaitouni S, Laraqui A, Boustany Y, et al. Potency and safety of KRAS G12C inhibitors in solid tumors: A systematic review. Clin Med Insights Oncol. 2025;19:11795549251331759.","journal-title":"Clin Med Insights Oncol"},{"issue":"10378","key":"3569_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733\u201346.","journal-title":"Lancet"},{"key":"3569_CR20","doi-asserted-by":"publisher","first-page":"1223433","DOI":"10.3389\/fimmu.2023.1223433","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu X, Song W, Cheng C, et al. Small molecular inhibitors for KRAS-mutant cancers. Front Immunol. 2023;14:1223433.","journal-title":"Front Immunol"},{"issue":"25","key":"3569_CR21","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"3569_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159.","journal-title":"Mol Cancer"},{"key":"3569_CR23","doi-asserted-by":"crossref","unstructured":"Jiao D, Yang S. Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation. Innovation (Cambridge (Mass.)) 2020;1(2).","DOI":"10.1016\/j.xinn.2020.100035"},{"issue":"3","key":"3569_CR24","doi-asserted-by":"publisher","first-page":"189108","DOI":"10.1016\/j.bbcan.2024.189108","volume":"1879","author":"W Ye","year":"2024","unstructured":"Ye W, Lu X, Qiao Y, et al. Activity and resistance to KRAS(G12C) inhibitors in non-small cell lung cancer and colorectal cancer. Biochim et Biophys Acta Rev Cancer. 2024;1879(3):189108.","journal-title":"Biochim et Biophys Acta Rev Cancer"},{"issue":"7","key":"3569_CR25","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, de la Fece F, Phat S, et al. Vertical pathway Inhibition overcomes adaptive feedback resistance to KRAS(G12C) Inhibition. Clin Cancer Res. 2020;26(7):1633\u201343.","journal-title":"Clin Cancer Res"},{"key":"3569_CR26","doi-asserted-by":"crossref","unstructured":"Dunnett-Kane V, Nicola P, Blackhall F et al. Mechanisms of resistance to KRAS(G12C) inhibitors. Cancers. 2021;13(1).","DOI":"10.3390\/cancers13010151"},{"key":"3569_CR27","doi-asserted-by":"publisher","first-page":"1107128","DOI":"10.3389\/fmed.2023.1107128","volume":"10","author":"PS Ramalingam","year":"2023","unstructured":"Ramalingam PS, Priyadharshini A, Emerson IA, et al. Potential biomarkers uncovered by bioinformatics analysis in Sotorasib resistant-pancreatic ductal adenocarcinoma. Front Med. 2023;10:1107128.","journal-title":"Front Med"},{"issue":"8","key":"3569_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, Sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16(8):1321\u201332.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"3569_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jtho.2021.05.002","volume":"16","author":"M Colombo","year":"2021","unstructured":"Colombo M, Ndembe G, Broggini M. Targeting and resistance: anticipating the expectable. J Thorac Oncol. 2021;16(8):1239\u201341.","journal-title":"J Thorac Oncol"},{"key":"3569_CR30","doi-asserted-by":"crossref","unstructured":"Liu Z, Lenz HJ, Yu J et al. Differential Response and Resistance to KRAS-Targeted Therapy. Mol Carcinogenesis. 2025.","DOI":"10.1002\/mc.23908"},{"key":"3569_CR31","doi-asserted-by":"publisher","first-page":"915512","DOI":"10.3389\/fonc.2022.915512","volume":"12","author":"H Zhuang","year":"2022","unstructured":"Zhuang H, Fan J, Li M, et al. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C). Front Oncol. 2022;12:915512.","journal-title":"Front Oncol"},{"key":"3569_CR32","doi-asserted-by":"publisher","first-page":"108050","DOI":"10.1016\/j.pharmthera.2021.108050","volume":"229","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Liu Q, et al. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Ther. 2022;229:108050.","journal-title":"Pharmacol Ther"},{"key":"3569_CR33","doi-asserted-by":"publisher","first-page":"1380584","DOI":"10.3389\/fonc.2024.1380584","volume":"14","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Kato S, Hong DS. KRAS G12C inhibitor combination therapies: current evidence and challenge. Front Oncol. 2024;14:1380584.","journal-title":"Front Oncol"},{"issue":"2","key":"3569_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.gendis.2021.08.011","volume":"10","author":"HY Li","year":"2023","unstructured":"Li HY, Qi WL, Wang YX, et al. Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead. Genes Dis. 2023;10(2):403\u201314.","journal-title":"Genes Dis"},{"issue":"11","key":"3569_CR35","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"3569_CR36","doi-asserted-by":"publisher","first-page":"113816","DOI":"10.1016\/j.ejmech.2021.113816","volume":"226","author":"G Fan","year":"2021","unstructured":"Fan G, Lou L, Song Z, et al. Targeting mutated GTPase KRAS in tumor therapies. Eur J Med Chem. 2021;226:113816.","journal-title":"Eur J Med Chem"},{"issue":"9","key":"3569_CR37","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","volume":"41","author":"J Mo","year":"2022","unstructured":"Mo J, Moye SL, McKay RM, et al. Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene. 2022;41(9):1235\u201351.","journal-title":"Oncogene"},{"key":"3569_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1101\/cshperspect.a031435","volume":"8","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ. The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8:9.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"3569_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","volume":"15","author":"K Parikh","year":"2022","unstructured":"Parikh K, Banna G, Liu SV, et al. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022;15(1):152.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3569_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1):143.","journal-title":"Mol Cancer"},{"issue":"1","key":"3569_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17\u201333.","journal-title":"Cell"},{"key":"3569_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cells13141221","volume":"13","author":"K Mondal","year":"2024","unstructured":"Mondal K, Posa MK, Shenoy RP, et al. KRAS mutation subtypes and their association with other driver mutations in oncogenic pathways. Cells. 2024;13:14.","journal-title":"Cells"},{"issue":"11","key":"3569_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jamaophthalmol.2021.4139","volume":"139","author":"J Rose-Nussbaumer","year":"2021","unstructured":"Rose-Nussbaumer J. Statistical significance vs clinical significance-That is the question. JAMA Ophthalmol. 2021;139(11):1235.","journal-title":"JAMA Ophthalmol"},{"issue":"37","key":"3569_CR44","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1080\/14796694.2024.2407280","volume":"20","author":"AK Tenekeci","year":"2024","unstructured":"Tenekeci AK, Unal AA, Ceylan F, et al. An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer. Future Oncol (London England). 2024;20(37):3019\u201338.","journal-title":"Future Oncol (London England)"},{"issue":"1","key":"3569_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1039\/D4CB00233D","volume":"6","author":"E Rennella","year":"2025","unstructured":"Rennella E, Henry C, Dickson CJ, et al. Dynamic conformational equilibria in the active States of KRAS and NRAS. RSC Chem Biol. 2025;6(1):106\u201318.","journal-title":"RSC Chem Biol"},{"issue":"13","key":"3569_CR46","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) Inhibition with Sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317.","journal-title":"N Engl J Med"},{"issue":"9","key":"3569_CR47","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(9):1101\u201310.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"3","key":"3569_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/17460441.2022.2029842","volume":"17","author":"K Haider","year":"2022","unstructured":"Haider K, Sharma A, Yar MS, et al. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design. Expert Opin Drug Discov. 2022;17(3):247\u201357.","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"3569_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.33696\/cancerimmunol.6.086","volume":"6","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Hong DS. Combining EGFR and KRAS G12C inhibitors for KRAS G12C mutated advanced colorectal cancer. J Cancer Immunol. 2024;6(2):62\u20139.","journal-title":"J Cancer Immunol"},{"key":"3569_CR50","doi-asserted-by":"publisher","first-page":"116842","DOI":"10.1016\/j.bcp.2025.116842","volume":"235","author":"YJ Kwon","year":"2025","unstructured":"Kwon YJ, Kim DY, Kim UI, et al. Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancer. Biochem Pharmacol. 2025;235:116842.","journal-title":"Biochem Pharmacol"},{"issue":"14","key":"3569_CR51","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1038\/s41388-021-01920-4","volume":"41","author":"YL Park","year":"2022","unstructured":"Park YL, Kim HP, Ock CY, et al. EMT-mediated regulation of CXCL1\/5 for resistance to anti-EGFR therapy in colorectal cancer. Oncogene. 2022;41(14):2026\u201338.","journal-title":"Oncogene"},{"issue":"5","key":"3569_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40265-024-02030-7","volume":"84","author":"J Torres-Jim\u00e9nez","year":"2024","unstructured":"Torres-Jim\u00e9nez J, Espinar JB, de Cabo HB, et al. Targeting KRAS(G12C) in Non-Small-Cell lung cancer: current standards and developments. Drugs. 2024;84(5):527\u201348.","journal-title":"Drugs"},{"issue":"23","key":"3569_CR53","doi-asserted-by":"publisher","first-page":"14404","DOI":"10.1021\/acs.jmedchem.0c01312","volume":"63","author":"H Chen","year":"2020","unstructured":"Chen H, Smaill JB, Liu T, et al. Small-Molecule inhibitors directly targeting KRAS as anticancer therapeutics. J Med Chem. 2020;63(23):14404\u201324.","journal-title":"J Med Chem"},{"issue":"2","key":"3569_CR54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/21541248.2019.1655883","volume":"12","author":"AA Gorfe","year":"2021","unstructured":"Gorfe AA, Cho KJ. Approaches to inhibiting oncogenic K-Ras. Small GTPases. 2021;12(2):96\u2013105.","journal-title":"Small GTPases"},{"issue":"7","key":"3569_CR55","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1073\/pnas.1918164117","volume":"117","author":"TH Tran","year":"2020","unstructured":"Tran TH, Alexander P, Dharmaiah S, et al. The small molecule BI-2852 induces a nonfunctional dimer of KRAS. Proc Natl Acad Sci USA. 2020;117(7):3363\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"3569_CR56","doi-asserted-by":"publisher","first-page":"15823","DOI":"10.1073\/pnas.1904529116","volume":"116","author":"D Kessler","year":"2019","unstructured":"Kessler D, Gmachl M, Mantoulidis A, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci USA. 2019;116(32):15823\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3569_CR57","doi-asserted-by":"crossref","unstructured":"Wallon L, Khan I, Teng KW et al. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the switch I\/II pocket. Proc Natl Acad Sci USA. 2022;119(43): e2204481119.","DOI":"10.1073\/pnas.2204481119"},{"issue":"21","key":"3569_CR58","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.4155\/fmc-2020-0221","volume":"12","author":"D Kessler","year":"2020","unstructured":"Kessler D, Bergner A, B\u00f6ttcher J, et al. Drugging all RAS isoforms with one pocket. Future Med Chem. 2020;12(21):1911\u201323.","journal-title":"Future Med Chem"},{"issue":"7968","key":"3569_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619(7968):160\u20136.","journal-title":"Nature"},{"issue":"2","key":"3569_CR60","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1021\/acsomega.8b03308","volume":"4","author":"MJ McCarthy","year":"2019","unstructured":"McCarthy MJ, Pagba CV, Prakash P, et al. Discovery of High-Affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding. ACS Omega. 2019;4(2):2921\u201330.","journal-title":"ACS Omega"},{"key":"3569_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/jci.insight.178535","volume":"9","author":"W Yang","year":"2024","unstructured":"Yang W, Zhang M, Zhang TX, et al. YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis. JCI Insight. 2024;9:24.","journal-title":"JCI Insight"},{"key":"3569_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cancers15205015","volume":"15","author":"VHF de Jesus","year":"2023","unstructured":"de Jesus VHF, Mathias-Machado MC, de Farias JPF, et al. Targeting KRAS in pancreatic ductal adenocarcinoma: the long road to cure. Cancers. 2023;15:20.","journal-title":"Cancers"},{"issue":"7886","key":"3569_CR63","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS(G12C) Inhibition. Nature. 2021;599(7886):679\u201383.","journal-title":"Nature"},{"issue":"25","key":"3569_CR64","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) Inhibition in cancer. N Engl J Med. 2021;384(25):2382\u201393.","journal-title":"N Engl J Med"},{"issue":"4","key":"3569_CR65","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/cbin.11524","volume":"45","author":"LN Pan","year":"2021","unstructured":"Pan LN, Ma YF, Li Z, et al. KRAS G12V mutation upregulates PD-L1 expression via TGF-\u03b2\/EMT signaling pathway in human non-small-cell lung cancer. Cell Biol Int. 2021;45(4):795\u2013803.","journal-title":"Cell Biol Int"},{"issue":"9","key":"3569_CR66","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11912-023-01436-y","volume":"25","author":"A Di Federico","year":"2023","unstructured":"Di Federico A, Ricciotti I, Favorito V, et al. Resistance to KRAS G12C Inhibition in Non-small cell lung cancer. Curr Oncol Rep. 2023;25(9):1017\u201329.","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"3569_CR67","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRAS(G12C) Inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021;11(8):1913\u201322.","journal-title":"Cancer Discov"},{"key":"3569_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms232213845","volume":"23","author":"G Tu","year":"2022","unstructured":"Tu G, Liu Q, Qiu Y, et al. In Silico study of the acquired resistance caused by the secondary mutations of KRAS G12C protein using long time molecular dynamics simulation and Markov state model analysis. Int J Mol Sci. 2022;23:22.","journal-title":"Int J Mol Sci"},{"key":"3569_CR69","doi-asserted-by":"crossref","unstructured":"Cong B, Stamou E, Pennel K et al. WNT Signalling Promotes NF-\u03baB Activation and Drug Resistance in KRAS-Mutant Colorectal Cancer. bioRxiv: the preprint server for biology. 2023.","DOI":"10.1101\/2023.12.21.572810"},{"issue":"11","key":"3569_CR70","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.dld.2023.03.011","volume":"55","author":"C Evrard","year":"2023","unstructured":"Evrard C, Ingrand P, Rochelle T, et al. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: the KRASCIPANC prospective study. Dig Liver Disease: Official J Italian Soc Gastroenterol Italian Association Study Liver. 2023;55(11):1562\u201372.","journal-title":"Dig Liver Disease: Official J Italian Soc Gastroenterol Italian Association Study Liver"},{"issue":"8","key":"3569_CR71","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jtho.2024.06.014","volume":"19","author":"SM Ernst","year":"2024","unstructured":"Ernst SM, von der Th\u00fcsen JH, Dubbink HJ, et al. Letter regarding clinical utility of Circulating tumor DNA in patients with advanced KRASG12C-Mutated NSCLC treated with Sotorasib. J Thorac Oncol. 2024;19(8):e29\u201330.","journal-title":"J Thorac Oncol"},{"key":"3569_CR72","doi-asserted-by":"publisher","first-page":"107293","DOI":"10.1016\/j.lungcan.2023.107293","volume":"184","author":"TKH Lim","year":"2023","unstructured":"Lim TKH, Skoulidis F, Kerr KM, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer (Amsterdam Netherlands). 2023;184:107293.","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"12","key":"3569_CR73","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, et al. KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy. Cell Rep. 2022;39(12):110993.","journal-title":"Cell Rep"},{"issue":"7","key":"3569_CR74","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 2022;29(7):875\u20138.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"3569_CR75","first-page":"355","volume":"12","author":"R Mishra","year":"2018","unstructured":"Mishra R, Patel H, Alanazi S, et al. HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018;12(1):355.","journal-title":"Oncol Rev"},{"issue":"1","key":"3569_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRASG12C-EGFR Inhibition in colorectal cancer. Cancer Discov. 2023;13(1):41\u201355.","journal-title":"Cancer Discov"},{"issue":"8","key":"3569_CR77","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade reverts resistance to KRAS(G12C) Inhibition in colorectal cancer. Cancer Discov. 2020;10(8):1129\u201339.","journal-title":"Cancer Discov"},{"issue":"4","key":"3569_CR78","first-page":"630","volume":"53","author":"W Li","year":"2023","unstructured":"Li W, Wu Y, Dai L, et al. SHP2 contributes to resistance of KRAS p.G12C-Driven lung cancer cells to MRTX849 by regulating \u03b2-catenin\/c-MYC axis. Ann Clin Lab Sci. 2023;53(4):630\u201340.","journal-title":"Ann Clin Lab Sci"},{"key":"3569_CR79","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1476-4598-13-105","volume":"13","author":"J Ma","year":"2014","unstructured":"Ma J, Lyu H, Huang J, et al. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer. 2014;13:105.","journal-title":"Mol Cancer"},{"issue":"1","key":"3569_CR80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41416-022-02032-w","volume":"128","author":"CH Chan","year":"2023","unstructured":"Chan CH, Chiou LW, Lee TY, et al. PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor Sotorasib. Br J Cancer. 2023;128(1):148\u201359.","journal-title":"Br J Cancer"},{"key":"3569_CR81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers16162796","volume":"16","author":"K Ashouri","year":"2024","unstructured":"Ashouri K, Wong A, Mittal P, et al. Exploring predictive and prognostic biomarkers in colorectal cancer: A comprehensive review. Cancers. 2024;16:16.","journal-title":"Cancers"},{"key":"3569_CR82","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2021;59:100796.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"issue":"3","key":"3569_CR83","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong X, Patel AS, Kim E, et al. Adeno-to-squamous transition drives resistance to KRAS Inhibition in LKB1 mutant lung cancer. Cancer Cell. 2024;42(3):413\u2013e4287.","journal-title":"Cancer Cell"},{"issue":"1","key":"3569_CR84","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/cam4.2682","volume":"9","author":"D Cai","year":"2020","unstructured":"Cai D, Hu C, Li L, et al. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. Cancer Med. 2020;9(1):84\u201393.","journal-title":"Cancer Med"},{"key":"3569_CR85","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","volume":"157","author":"A Di Federico","year":"2021","unstructured":"Di Federico A, De Giglio A, Parisi C, et al. STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: prognostic rather than predictive? Eur J Cancer. 2021;157:108\u201313.","journal-title":"Eur J Cancer"},{"key":"3569_CR86","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2022.06.010","volume":"170","author":"VC de Cordeiro","year":"2022","unstructured":"de Cordeiro VC, Corassa M, Saldanha E, et al. STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung Cancer. 2022;170:114\u201321.","journal-title":"Lung Cancer"},{"key":"3569_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijms241512030","volume":"24","author":"F Bteich","year":"2023","unstructured":"Bteich F, Mohammadi M, Li T, et al. Targeting KRAS in colorectal cancer: A bench to bedside review. Int J Mol Sci. 2023;24:15.","journal-title":"Int J Mol Sci"},{"key":"3569_CR88","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/jpm13061010","volume":"13","author":"P Manolakos","year":"2023","unstructured":"Manolakos P, Ward LD. A critical review of the prognostic and predictive implications of KRAS and STK11 mutations and Co-Mutations in metastatic Non-Small lung cancer. J Personalized Med. 2023;13:6.","journal-title":"J Personalized Med"},{"key":"3569_CR89","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm11144003","volume":"11","author":"Y Sun","year":"2022","unstructured":"Sun Y, Li Z, Jian H, et al. Impact of KRAS mutation subtypes and Co-Occurring mutations on response and outcome in advanced NSCLC patients following First-Line treatment. J Clin Med. 2022;11:14.","journal-title":"J Clin Med"},{"issue":"2","key":"3569_CR90","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/SLA.0b013e3182827a65","volume":"258","author":"M Oshima","year":"2013","unstructured":"Oshima M, Okano K, Muraki S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A\/p16, TP53, and SMAD4\/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013;258(2):336\u201346.","journal-title":"Ann Surg"},{"issue":"7","key":"3569_CR91","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1078-0432.CCR-16-2070","volume":"23","author":"E Borazanci","year":"2017","unstructured":"Borazanci E, Dang CV, Robey RW, et al. Pancreatic cancer: A riddle wrapped in a mystery inside an enigma. Clin Cancer Res. 2017;23(7):1629\u201337.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3569_CR92","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1245\/s10434-021-11081-z","volume":"29","author":"S Shoucair","year":"2022","unstructured":"Shoucair S, Habib JR, Pu N, et al. Comprehensive analysis of somatic mutations in driver genes of resected pancreatic ductal adenocarcinoma reveals KRAS G12D and mutant TP53 combination as an independent predictor of clinical outcome. Ann Surg Oncol. 2022;29(4):2720\u201331.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"3569_CR93","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.21037\/tcr-24-600","volume":"13","author":"X Wan","year":"2024","unstructured":"Wan X, Zhang X, Xu M, et al. Unveiling the role of KRAS in Chinese colorectal cancer patients: a positive influence on tumor mutational burden. Transl Cancer Res. 2024;13(9):4752\u201362.","journal-title":"Transl Cancer Res"},{"key":"3569_CR94","doi-asserted-by":"publisher","first-page":"116783","DOI":"10.1016\/j.biopha.2024.116783","volume":"176","author":"M Yang","year":"2024","unstructured":"Yang M, Mu Y, Yu X, et al. Survival strategies: how tumor hypoxia microenvironment orchestrates angiogenesis. Biomed Pharmacother. 2024;176:116783.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"3569_CR95","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3569_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00428-021-03030-8","volume":"478","author":"H Uruga","year":"2021","unstructured":"Uruga H, Mino-Kenudson M. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. Virchows Arch. 2021;478(1):31\u201344.","journal-title":"Virchows Arch"},{"key":"3569_CR97","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3569_CR98","doi-asserted-by":"publisher","first-page":"15455","DOI":"10.1038\/s41598-021-94671-x","volume":"11","author":"T Katopodi","year":"2021","unstructured":"Katopodi T, Petanidis S, Domvri K, et al. Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3\/PTK2 immunosuppressive circuit. Sci Rep. 2021;11(1):15455.","journal-title":"Sci Rep"},{"issue":"11","key":"3569_CR99","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1111\/1759-7714.13978","volume":"12","author":"C Kamimaki","year":"2021","unstructured":"Kamimaki C, Kobayashi N, Hirata M, et al. T-cell response to Phytohemagglutinin in the interferon-\u03b3 release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 2021;12(11):1726\u201334.","journal-title":"Thorac Cancer"},{"issue":"5","key":"3569_CR100","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","volume":"24","author":"AL de Gomes","year":"2022","unstructured":"de Gomes AL, Cerd\u00e1 S, de Miguel M. New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors. Curr Oncol Rep. 2022;24(5):651\u20138.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"3569_CR101","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, et al. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32(12):4235\u201355.","journal-title":"Mol Ther"},{"issue":"Pt 2","key":"3569_CR102","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365.","journal-title":"Int Immunopharmacol"},{"issue":"20","key":"3569_CR103","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-21-0856","volume":"27","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Yonesaka K, Teramura T, et al. KRAS inhibitor resistance in MET-Amplified KRAS (G12C) Non-Small cell lung cancer induced by RAS- and Non-RAS-Mediated cell signaling mechanisms. Clin Cancer Research: Official J Am Association Cancer Res. 2021;27(20):5697\u2013707.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"3569_CR104","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fcell.2020.00152","volume":"8","author":"X Huang","year":"2020","unstructured":"Huang X, Li E, Shen H, et al. Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement. Front Cell Dev Biology. 2020;8:152.","journal-title":"Front Cell Dev Biology"},{"issue":"8","key":"3569_CR105","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2017.04.031","volume":"12","author":"GD Lee","year":"2017","unstructured":"Lee GD, Lee SE, Oh DY, et al. Exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values. J Thorac Oncol. 2017;12(8):1233\u201346.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"3569_CR106","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/ijc.34225","volume":"151","author":"P Dias Carvalho","year":"2022","unstructured":"Dias Carvalho P, Martins F, Mendon\u00e7a S, et al. Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF\/C-MET axis. Int J Cancer. 2022;151(10):1810\u201323.","journal-title":"Int J Cancer"},{"issue":"10","key":"3569_CR107","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1541-7786.MCR-15-0506","volume":"14","author":"JY Kim","year":"2016","unstructured":"Kim JY, Welsh EA, Fang B, et al. Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-Driven AKT signaling in KRAS-Mutant lung cancer. Mol Cancer Res. 2016;14(10):1019\u201329.","journal-title":"Mol Cancer Res"},{"issue":"7782","key":"3569_CR108","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"issue":"3","key":"3569_CR109","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ccell.2024.02.014","volume":"42","author":"F Hu","year":"2024","unstructured":"Hu F, Lito P. Insights into how adeno-squamous transition drives KRAS inhibitor resistance. Cancer Cell. 2024;42(3):330\u20132.","journal-title":"Cancer Cell"},{"issue":"22","key":"3569_CR110","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi Y, Ito K, Hayashi Y, et al. Epithelial-to-Mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-Mutant Non-Small cell lung cancer. Clin Cancer Res. 2020;26(22):5962\u201373.","journal-title":"Clin Cancer Res"},{"key":"3569_CR111","doi-asserted-by":"publisher","first-page":"1004669","DOI":"10.3389\/fonc.2022.1004669","volume":"12","author":"W Ning","year":"2022","unstructured":"Ning W, Marti TM, Dorn P, et al. Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit. Front Oncol. 2022;12:1004669.","journal-title":"Front Oncol"},{"issue":"33","key":"3569_CR112","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1038\/onc.2010.218","volume":"29","author":"Y Wang","year":"2010","unstructured":"Wang Y, Ngo VN, Marani M, et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene. 2010;29(33):4658\u201370.","journal-title":"Oncogene"},{"issue":"14","key":"3569_CR113","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2174\/1381612826666200206095400","volume":"26","author":"A Mahmoud","year":"2020","unstructured":"Mahmoud A, Elkhalifa D, Alali F, et al. Novel polymethoxylated Chalcones as potential compounds against KRAS-Mutant colorectal cancers. Curr Pharm Des. 2020;26(14):1622\u201333.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"3569_CR114","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/curroncol31040150","volume":"31","author":"LJ Ash","year":"2024","unstructured":"Ash LJ, Busia-Bourdain O, Okpattah D, et al. Biology, inhibition, and mechanisms of inhibitor resistance. Curr Oncol. 2024;31(4):2024\u201346.","journal-title":"Curr Oncol"},{"issue":"12","key":"3569_CR115","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","volume":"11","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A, Taniguchi H, Zhan YA, et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;11(12):3028\u201347.","journal-title":"Cancer Discov"},{"issue":"4","key":"3569_CR116","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10147-017-1156-4","volume":"22","author":"K Kawada","year":"2017","unstructured":"Kawada K, Toda K, Sakai Y. Targeting metabolic reprogramming in KRAS-driven cancers. Int J Clin Oncol. 2017;22(4):651\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"3569_CR117","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","volume":"24","author":"Q Ma","year":"2025","unstructured":"Ma Q, Zhang W, Wu K, et al. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol Cancer. 2025;24(1):14.","journal-title":"Mol Cancer"},{"issue":"6427","key":"3569_CR118","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.aav0173","volume":"363","author":"CK Lee","year":"2019","unstructured":"Lee CK, Jeong SH, Jang C, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science. 2019;363(6427):644\u20139.","journal-title":"Science"},{"key":"3569_CR119","doi-asserted-by":"crossref","unstructured":"Afonso J, Gon\u00e7alves C, Costa M et al. Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy. Cancers (Basel) 2023; 15(3).","DOI":"10.3390\/cancers15030982"},{"issue":"756","key":"3569_CR120","doi-asserted-by":"publisher","first-page":"eabj3490","DOI":"10.1126\/scisignal.abj3490","volume":"15","author":"DY Moss","year":"2022","unstructured":"Moss DY, McCann C, Kerr EM. Rerouting the drug response: overcoming metabolic adaptation in KRAS-mutant cancers. Sci Signal. 2022;15(756):eabj3490.","journal-title":"Sci Signal"},{"key":"3569_CR121","doi-asserted-by":"publisher","first-page":"107252","DOI":"10.1016\/j.phrs.2024.107252","volume":"206","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ye S, Wu Y, et al. Cyclopeptide RA-V from rubia yunnanensis restores activity of adagrasib against colorectal cancer by reducing the expression of Nrf2. Pharmacol Res. 2024;206:107252.","journal-title":"Pharmacol Res"},{"issue":"11","key":"3569_CR122","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.7150\/thno.73089","volume":"12","author":"W Chong","year":"2022","unstructured":"Chong W, Zhu X, Ren H, et al. Integrated multi-omics characterization of KRAS mutant colorectal cancer. Theranostics. 2022;12(11):5138\u201354.","journal-title":"Theranostics"},{"issue":"1","key":"3569_CR123","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-025-06089-y","volume":"23","author":"L Tian","year":"2025","unstructured":"Tian L, Liu C, Zheng S, et al. KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors. J Transl Med. 2025;23(1):82.","journal-title":"J Transl Med"},{"key":"3569_CR124","doi-asserted-by":"crossref","unstructured":"Ho CSL, T\u00fcns AI, Schildhaus UH, et al. HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2. Eur J Cancer (Oxford England: 1990). 2021;159:16\u201323.","DOI":"10.1016\/j.ejca.2021.10.003"},{"issue":"9","key":"3569_CR125","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41388-023-02924-y","volume":"43","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu L, Pei J, et al. Tissue factor overexpression promotes resistance to KRAS-G12C Inhibition in non-small cell lung cancer. Oncogene. 2024;43(9):668\u201381.","journal-title":"Oncogene"},{"key":"3569_CR126","doi-asserted-by":"crossref","unstructured":"Lin P, Cheng W, Qi X et al. Bioinformatics and experimental validation for identifying biomarkers associated with AMG510 (Sotorasib) resistance in KRAS(G12C)-Mutated lung adenocarcinoma. Int J Mol Sci 2024, 25 (3).","DOI":"10.3390\/ijms25031555"},{"key":"3569_CR127","doi-asserted-by":"publisher","first-page":"103361","DOI":"10.1016\/j.redox.2024.103361","volume":"77","author":"Y Bian","year":"2024","unstructured":"Bian Y, Shan G, Bi G, et al. Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. Redox Biol. 2024;77:103361.","journal-title":"Redox Biol"},{"issue":"11","key":"3569_CR128","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, et al. Mechanisms of resistance to oncogenic KRAS Inhibition in pancreatic cancer. Cancer Discov. 2024;14(11):2135\u201361.","journal-title":"Cancer Discov"},{"issue":"9","key":"3569_CR129","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1158\/1078-0432.CCR-20-3872","volume":"27","author":"HS Solanki","year":"2021","unstructured":"Solanki HS, Welsh EA, Fang B, et al. Cell Type-specific adaptive signaling responses to KRAS(G12C) Inhibition. Clin Cancer Res. 2021;27(9):2533\u201348.","journal-title":"Clin Cancer Res"},{"key":"3569_CR130","doi-asserted-by":"crossref","unstructured":"Riedl JM, de la Fece F, Lin JJ et al. Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors. Ann Oncol 2025.","DOI":"10.1016\/j.annonc.2025.01.020"},{"issue":"1","key":"3569_CR131","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/curroncol30010037","volume":"30","author":"M Knetki-Wr\u00f3blewska","year":"2022","unstructured":"Knetki-Wr\u00f3blewska M, Tabor S, P\u0142u\u017ca\u0144ski A, et al. Efficacy of immunotherapy in Second-Line treatment of KRAS-Mutated patients with Non-Small-Cell lung Cancer-Data from daily practice. Curr Oncol (Toronto Ont). 2022;30(1):462\u201375.","journal-title":"Curr Oncol (Toronto Ont)"},{"issue":"2","key":"3569_CR132","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/03008916231204441","volume":"110","author":"A Olsen","year":"2024","unstructured":"Olsen A, Lebedeva A, Nosova P, et al. Impact of the STK11\/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Tumori. 2024;110(2):146\u201352.","journal-title":"Tumori"},{"issue":"10","key":"3569_CR133","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/0008-5472.CAN-20-2370","volume":"81","author":"B Yang","year":"2021","unstructured":"Yang B, Li X, Fu Y, et al. MEK Inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors. Cancer Res. 2021;81(10):2714\u201329.","journal-title":"Cancer Res"},{"key":"3569_CR134","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijms19123920","volume":"19","author":"C Modica","year":"2018","unstructured":"Modica C, Tortarolo D, Comoglio PM, et al. MET\/HGF Co-Targeting in pancreatic cancer: A tool to provide insight into the tumor\/stroma crosstalk. Int J Mol Sci. 2018;19:12.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3569_CR135","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, Uboha NV, Pelster MS, et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-Mutated metastatic colorectal cancer. Cancer Discov. 2024;14(6):982\u201393.","journal-title":"Cancer Discov"},{"issue":"1","key":"3569_CR136","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1568026614666140423121525","volume":"9","author":"F Meriggi","year":"2014","unstructured":"Meriggi F, Vermi W, Bertocchi P, et al. The emerging role of NRAS mutations in colorectal cancer patients selected for Anti-EGFR therapies. Rev Recen Clin Trial. 2014;9(1):8\u201312.","journal-title":"Rev Recen Clin Trial"},{"key":"3569_CR137","doi-asserted-by":"publisher","first-page":"1398419","DOI":"10.3389\/fphar.2024.1398419","volume":"15","author":"A R\u00edos-Hoyo","year":"2024","unstructured":"R\u00edos-Hoyo A, Monzon\u00eds X, Vidal J, et al. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharmacol. 2024;15:1398419.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3569_CR138","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/onco.13631","volume":"26","author":"EMJ van Brummelen","year":"2021","unstructured":"van Brummelen EMJ, Huijberts S, van Herpen C, et al. Phase I study of Afatinib and selumetinib in patients with KRAS-Mutated colorectal, Non-Small cell lung, and pancreatic cancer. Oncologist. 2021;26(4):290\u2013e545.","journal-title":"Oncologist"},{"issue":"1","key":"3569_CR139","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40478-025-01993-2","volume":"13","author":"C Migliarese","year":"2025","unstructured":"Migliarese C, Sadeh Y, Torrini C, et al. Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A. Acta Neuropathol Commun. 2025;13(1):88.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"3569_CR140","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stem.2023.11.011","volume":"31","author":"X Duan","year":"2024","unstructured":"Duan X, Zhang T, Feng L, et al. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Cell Stem Cell. 2024;31(1):71\u2013e888.","journal-title":"Cell Stem Cell"},{"key":"3569_CR141","doi-asserted-by":"publisher","first-page":"101106","DOI":"10.1016\/j.currproblcancer.2024.101106","volume":"51","author":"E Harris","year":"2024","unstructured":"Harris E, Thawani R. Current perspectives of KRAS in non-small cell lung cancer. Curr Probl Cancer. 2024;51:101106.","journal-title":"Curr Probl Cancer"},{"key":"3569_CR142","doi-asserted-by":"publisher","first-page":"786728","DOI":"10.3389\/fcell.2021.786728","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang YY, Chen Y, et al. TGF-\u03b2 signaling and resistance to cancer therapy. Front Cell Dev Biology. 2021;9:786728.","journal-title":"Front Cell Dev Biology"},{"issue":"1","key":"3569_CR143","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388(1):44\u201354.","journal-title":"N Engl J Med"},{"key":"3569_CR144","doi-asserted-by":"crossref","unstructured":"Falchook G, Li BT, Marrone KA et al. OA03.03 Sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-Mutated NSCLC and other solid tumors. 2022;17(9-Sup):1.","DOI":"10.1016\/j.jtho.2022.07.022"},{"key":"3569_CR145","doi-asserted-by":"crossref","unstructured":"Ramalingam S, Fakih M, Strickler J et al. Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated solid tumors. 2021;20(12-Sup):1.","DOI":"10.1158\/1535-7163.TARG-21-P05-01"},{"issue":"9","key":"3569_CR146","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","volume":"17","author":"BT Li","year":"2022","unstructured":"Li BT, Falchook GS, Durm GA, et al. OA03.06 codebreak 100\/101: first report of safety\/efficacy of Sotorasib in combination with pembrolizumab or Atezolizumab in advanced KRAS p.G12C NSCLC. J Thorac Oncol. 2022;17(9):S10\u20131.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3569_CR147","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1158\/0008-5472.CAN-20-3665","volume":"81","author":"J Zhou","year":"2021","unstructured":"Zhou J, Li Q, Cao Y. Spatiotemporal heterogeneity across metastases and Organ-Specific response informs drug efficacy and patient survival in colorectal cancer. Cancer Res. 2021;81(9):2522\u201333.","journal-title":"Cancer Res"},{"issue":"3","key":"3569_CR148","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/humu.22496","volume":"35","author":"V Kosmidou","year":"2014","unstructured":"Kosmidou V, Oikonomou E, Vlassi M, et al. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum Mutat. 2014;35(3):329\u201340.","journal-title":"Hum Mutat"},{"issue":"76","key":"3569_CR149","first-page":"207","volume":"14","author":"M Berg","year":"2012","unstructured":"Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS\/BRAF and PI3K\/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med. 2012;14(76):207\u201314.","journal-title":"Discov Med"},{"key":"3569_CR150","doi-asserted-by":"publisher","first-page":"1402128","DOI":"10.3389\/fonc.2024.1402128","volume":"14","author":"SA Long","year":"2024","unstructured":"Long SA, Amparo AM, Goodhart G, et al. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Front Oncol. 2024;14:1402128.","journal-title":"Front Oncol"},{"issue":"33","key":"3569_CR151","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1111\/1759-7714.15123","volume":"14","author":"Y Amino","year":"2023","unstructured":"Amino Y, Low SK, Ninomiya H, et al. Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thorac Cancer. 2023;14(33):3317\u201322.","journal-title":"Thorac Cancer"},{"issue":"2","key":"3569_CR152","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ijc.32510","volume":"146","author":"K Mardinian","year":"2020","unstructured":"Mardinian K, Okamura R, Kato S, et al. Temporal and Spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020;146(2):566\u201376.","journal-title":"Int J Cancer"},{"issue":"8","key":"3569_CR153","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/PAI.0000000000000475","volume":"26","author":"AM Valentini","year":"2018","unstructured":"Valentini AM, Cavalcanti E, Di Maggio M, et al. RAS-expanded mutations and HER2 expression in metastatic colorectal cancer: A new step of precision medicine. Appl Immunohistochem Mol Morphol AIMM. 2018;26(8):539\u201344.","journal-title":"Appl Immunohistochem Mol Morphol: AIMM"},{"issue":"11","key":"3569_CR154","doi-asserted-by":"publisher","first-page":"e981","DOI":"10.1093\/oncolo\/oyad138","volume":"28","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Yoshino T, Stevinson K, et al. Prevalence of KRAS G12C mutation and Co-mutations and associated clinical outcomes in patients with colorectal cancer: A systematic literature review. Oncologist. 2023;28(11):e981\u201394.","journal-title":"Oncologist"},{"key":"3569_CR155","doi-asserted-by":"crossref","unstructured":"Abbott C, Bedi N, Wang J et al. 20 Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy. 2021.","DOI":"10.1136\/jitc-2021-SITC2021.020"},{"key":"3569_CR156","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers13112541","volume":"13","author":"A Addeo","year":"2021","unstructured":"Addeo A, Banna GL, Friedlaender A. KRAS G12C mutations in NSCLC: from target to resistance. Cancers. 2021;13:11.","journal-title":"Cancers"},{"issue":"7","key":"3569_CR157","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1158\/0008-5472.CAN-20-2222","volume":"81","author":"R Shrestha","year":"2021","unstructured":"Shrestha R, Llaurado Fernandez M, Dawson A, et al. Multiomics characterization of Low-Grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Cancer Res. 2021;81(7):1681\u201394.","journal-title":"Cancer Res"},{"key":"3569_CR158","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Bayona R, Catal\u00e1n C, Cobos MA et al. Pharmacogenomics in solid tumors: A comprehensive review of genetic variability and its clinical implications. Cancers 2025, 17 (6).","DOI":"10.3390\/cancers17060913"},{"key":"3569_CR159","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","volume":"154","author":"KM Kerr","year":"2021","unstructured":"Kerr KM, Bibeau F, Thunnissen E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer (Amsterdam Netherlands). 2021;154:161\u201375.","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"4\u20135","key":"3569_CR160","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/path.6293","volume":"263","author":"I Felipe","year":"2024","unstructured":"Felipe I, Real FX. PDAC heterogeneity resolved spatially at the single-cell level: new biological answers, new questions on optimal translation(\u2020). J Pathol. 2024;263(4\u20135):397\u20139.","journal-title":"J Pathol"},{"issue":"24","key":"3569_CR161","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1158\/0008-5472.CAN-23-1127","volume":"83","author":"A Prahallad","year":"2023","unstructured":"Prahallad A, Weiss A, Voshol H, et al. CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in Non-Small cell lung cancer. Cancer Res. 2023;83(24):4130\u201341.","journal-title":"Cancer Res"},{"issue":"224","key":"3569_CR162","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, et al. Detection of Circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.","journal-title":"Sci Transl Med"},{"key":"3569_CR163","doi-asserted-by":"crossref","unstructured":"Junca A, Tachon G, Evrard C et al. Detection of colorectal cancer and advanced adenoma by liquid biopsy (Decalib Study): The ddPCR Challenge. Cancers 2020;12(6).","DOI":"10.3390\/cancers12061482"},{"issue":"49","key":"3569_CR164","doi-asserted-by":"publisher","first-page":"19294","DOI":"10.1021\/acs.analchem.4c03006","volume":"96","author":"A Hu","year":"2024","unstructured":"Hu A, Zhang J, Zhang L, et al. Efficient cancer biomarker screening and multicancer detection enabled by a multidimensional serum proteomic strategy. Anal Chem. 2024;96(49):19294\u2013303.","journal-title":"Anal Chem"},{"issue":"7","key":"3569_CR165","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1021\/acsomega.2c06659","volume":"8","author":"PA Patkulkar","year":"2023","unstructured":"Patkulkar PA, Subbalakshmi AR, Jolly MK, et al. Mapping Spatiotemporal heterogeneity in tumor profiles by integrating High-Throughput imaging and omics analysis. ACS Omega. 2023;8(7):6126\u201338.","journal-title":"ACS Omega"},{"key":"3569_CR166","doi-asserted-by":"publisher","first-page":"1357898","DOI":"10.3389\/fonc.2024.1357898","volume":"14","author":"KB Sreter","year":"2024","unstructured":"Sreter KB, Catarata MJ, von Laffert M, et al. Resistance to KRAS Inhibition in advanced non-small cell lung cancer. Front Oncol. 2024;14:1357898.","journal-title":"Front Oncol"},{"key":"3569_CR167","doi-asserted-by":"crossref","unstructured":"Sch\u00f6neck M, Rehbach N, Lotter-Becker L et al. Machine Learning-Based radiomics analysis for identifying KRAS mutations in Non-Small-Cell lung cancer from CT images: challenges, insights and implications. Life (Basel Switzerland) 2025;15(1).","DOI":"10.3390\/life15010083"},{"issue":"7404","key":"3569_CR168","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532\u20136.","journal-title":"Nature"},{"issue":"5","key":"3569_CR169","doi-asserted-by":"publisher","first-page":"649","DOI":"10.5603\/rpor.102823","volume":"29","author":"R Nema","year":"2024","unstructured":"Nema R. An omics-based tumor microenvironment approach and its prospects. Rep Practical Oncol Radiother. 2024;29(5):649\u201350.","journal-title":"Rep Practical Oncol Radiother"},{"key":"3569_CR170","doi-asserted-by":"crossref","unstructured":"Srivastava S, Anand A, Kandhula AG et al. Precision medicine in colorectal cancer: targeted therapies and biomarker insights. Curr Cancer Drug Targets 2025.","DOI":"10.2174\/0115680096338273241224061021"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03569-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:04:12Z","timestamp":1759925052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03569-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":170,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3569"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03569-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1834"}}